Reply to M. Kazi et al, O. Sütcüoğlu et al, and J. Socha et al

Affiliations

¹ Amr Aref, MD, Rectal Cancer Group, Van Elslander Cancer Center, Ascension St John Hospital, Detroit, MI, Radiation Oncology, Van Elslander Cancer Center, Ascension St John Hospital, Detroit, MI; and Ahmed Abdalla, MD, Interdisciplinary Oncology, Mitchell Cancer Center, University of South Alabama, Mobile, AL.

Comment

Amr Aref et al. J Clin Oncol. 2023.

. 2023 Jan 10;41(2):418-419.

doi: 10.1200/JCO.22.01435. Epub 2022 Sep 20.

¹ Amr Aref, MD, Rectal Cancer Group, Van Elslander Cancer Center, Ascension St John Hospital, Detroit, MI, Radiation Oncology, Van Elslander Cancer Center, Ascension St John Hospital, Detroit, MI; and Ahmed Abdalla, MD, Interdisciplinary Oncology, Mitchell Cancer Center, University of South Alabama, Mobile, AL.

No abstract available

Comment on

Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?
Sütcüoğlu O, Rustamova Cennet N, Özet A, Özdemir N, Yazıcı O. Sütcüoğlu O, et al. J Clin Oncol. 2023 Jan 10;41(2):416-417. doi: 10.1200/JCO.22.01260. Epub 2022 Sep 20. J Clin Oncol. 2023. PMID: 36126234 No abstract available.
Total Neoadjuvant Therapy for All Rectal Cancers: Is This the Way Ahead of the OPRA Trial?
Kazi M, Saklani A. Kazi M, et al. J Clin Oncol. 2023 Jan 10;41(2):415-416. doi: 10.1200/JCO.22.01166. Epub 2022 Sep 20. J Clin Oncol. 2023. PMID: 36126238 No abstract available.
Radio- or Chemotherapy Dose Escalation for Organ Preservation in Rectal Cancer?
Socha J, Żółciak-Siwińska A, Bujko K. Socha J, et al. J Clin Oncol. 2023 Jan 10;41(2):417. doi: 10.1200/JCO.22.01296. Epub 2022 Sep 20. J Clin Oncol. 2023. PMID: 36126242 No abstract available.